From exclusion to inclusion: understanding and reconnecting breast cancer patients who stopped follow-up
Official title: A Comprehensive Analysis of Follow-up Outcomes, Continuity and Updated Survivorship in Breast Cancer
Run by Basavatarakam Indo American Cancer Hospital & Research Institute · NCT06927102 · Data updated 2026-11-12
This project will try outreach by phone, message, or email to see if women treated for non-metastatic breast cancer at a Hyderabad tertiary centre who stopped follow-up can be re-engaged.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Basavatarakam Indo American Cancer Hospital & Research Institute Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hyderabad, Telangana) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | September 2025 |
| Study ends | October 2025 |
| Registry record updated | September 19, 2025 |
| Trial ID | NCT06927102 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women diagnosed with non-metastatic breast cancer between 2017 and 2018 who were treated at Basavatarakam Indo American Cancer Hospital and are currently classified as lost-to-follow-up and willing to re-engage.
✕Probably not a fit
Patients who have permanently relocated outside the study region, received ongoing care at another centre, have incomplete records, or cannot be contacted are unlikely to benefit from the outreach approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective cohort analysis of women diagnosed with non-metastatic breast cancer in 2017–2018 who received treatment at a single tertiary cancer centre. Baseline demographic, tumor, stage, subtype, and treatment data will be collected from medical records. Phase I will document annual follow-up visits through December 2024 using hospital records and EMR to determine five-year loss-to-follow-up rates and associated factors. Phase II will identify patients categorized as lost-to-follow-up, extract additional socioeconomic and geographic variables, and undertake proactive outreach to obtain consent, current health status, and patient-reported barriers to follow-up.
Why it matters
Potential benefit: If successful, proactive outreach could bring more patients back into follow-up care, enabling earlier detection of recurrence and improved long-term management.
How similar studies have gone: Similar proactive outreach programs have reduced loss-to-follow-up in other cancer and chronic disease settings, though robust local evidence from Indian tertiary centres is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients newly diagnosed with non-metastatic breast cancer between 2017-2018 2. Patients categorized as "lost-to-follow-up", as defined above 3. Patients willing to participate upon re-engagement Exclusion Criteria: 1. Patients with incomplete medical records 2. Patients who have taken part of the treatment at another hospital/centre 3. Patients who have relocated permanently out of the study region Withdrawal Criteria: 1\. Patient withdraws consent
Where it's running
-
Basavatarakam Indo American Cancer Hospital & Research Institute
Hyderabad, Telangana, India Recruiting
Study contacts
- Principal investigator: Nisha Hariharan, MS,HBNI Fellow Breast Oncology — Basavatarakam Indo American Cancer Hospital & Research Institute
- Study coordinator: Clinical Trial Co-ordinator, Pharm D
- Email: research.oncology@basavatarakam.org
- Phone: 040-23551235
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mobile health navigation to improve breast cancer screening in Kenyan women
This study tests m-Health patient navigation tools to help women in Kenya access breast cancer screening and early detection services.
-
Blended e-Health Program to Help Women with Breast or Gynecologic Cancer Manage Fear of Cancer Progression
This trial tests a blended online and group program to see if it helps women with breast or gynecologic cancer feel less fear that their cancer could grow or spread.
-
Environmental exposure checks in high-risk and early-onset breast cancer care
This study tests how patients and providers feel about using environmental exposure risk data in breast cancer care for women at average/high risk or with early-onset breast cancer.
-
CSF sample collection from people with metastatic breast cancer to see brain metastasis risk
This study tests whether spinal fluid and other samples can help predict brain metastases in adults with metastatic HER2-positive or triple-negative breast cancer who have not yet shown brain involvement.
-
Body composition and outcomes after breast reconstruction
This study will see if detailed body composition measurements can help predict complications after mastectomy with immediate breast reconstruction in adult women.
-
Support tool for women with HR+ breast cancer on long-term endocrine therapy
This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.